G-CSF and Plerixafor with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias.

Trial Profile

G-CSF and Plerixafor with Busulfan and Fludarabine for Allogeneic Stem Cell Transplantation for Myeloid Leukemias.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Apr 2015

At a glance

  • Drugs Plerixafor (Primary) ; Antithymocyte globulin; Busulfan; Filgrastim; Fludarabine; Tacrolimus; Tacrolimus
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Oct 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Jun 2012 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
    • 21 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top